gs3-02. updated overall survival (os) results from the phase 3 phoebe trial
Published 1 year ago • 61 plays • Length 8:15Download video MP4
Download video MP3
Similar videos
-
2:16
sabcs 2022: destiny-breast02 destiny-breast03
-
0:55
key highlights from sabcs 2022
-
4:08
sabcs 2022 highlights
-
1:25
sabcs 2022: clinical trial highlights
-
1:06
sabcs 2022 highlights
-
0:32
highlights in her2-low breast cancer at sabcs 2022
-
0:51
sabcs 2022: key highlights
-
56:30
ask the expert: sabcs highlights
-
57:03
ask the expert: early-stage hormone receptor-positive, her2-positive & triple-positive breast cancer
-
1:01:34
er breast cancer case panel discussion | 2022 best of breast conference
-
22:36
cancer diaries |chemotherapy side effects and how i dealt with them |urdu/hindi
-
0:44
what to look out for at sabcs 2022
-
1:17
key trial updates in serds in er /her2- breast cancer from sabcs 2022
-
0:56
the san antonio breast cancer symposium (sabcs) 2022
-
6:17
sara tolaney, sabcs 2022: adjuvant paclitaxel and trastuzumab for node-negative her2 breast cancer
-
2:57
key data from the san antonio breast cancer symposium (sabcs) 2022
-
1:16
key data at sabcs 2022
-
0:54
what is progression free survival (pfs) as it relates to metastatic breast cancer therapy?
-
1:51:16
dr. bora lim | challenging types of breast cancer | sabcs 2022 | education session
-
6:23
sabcs 2022: new breast cancer treatments
-
1:28
highlights from sabcs 2020